258 related articles for article (PubMed ID: 32915420)
21. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases.
Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF
Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781
[TBL] [Abstract][Full Text] [Related]
22. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
23. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract][Full Text] [Related]
24. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
[TBL] [Abstract][Full Text] [Related]
25. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Gambacorti-Passerini C; Orlov S; Zhang L; Braiteh F; Huang H; Esaki T; Horibe K; Ahn JS; Beck JT; Edenfield WJ; Shi Y; Taylor M; Tamura K; Van Tine BA; Wu SJ; Paolini J; Selaru P; Kim TM
Am J Hematol; 2018 May; 93(5):607-614. PubMed ID: 29352732
[TBL] [Abstract][Full Text] [Related]
26. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
27. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
28. A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
Zhao S; Liu W; Li S; Shi T; Chen Q; Li Q; Sun L; Ren D; Song Z; Huang C; Xu S
Cancer Res Treat; 2021 Apr; 53(2):601-606. PubMed ID: 33091968
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R
Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015
[TBL] [Abstract][Full Text] [Related]
30. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations.
Debonis SA; Bongiovanni A; Pieri F; Fausti V; De Vita A; Riva N; Gurrieri L; Vanni S; Diano D; Mercatali L; Ibrahim T
Medicine (Baltimore); 2021 May; 100(20):e25972. PubMed ID: 34011083
[TBL] [Abstract][Full Text] [Related]
31. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
32. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract][Full Text] [Related]
33. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory myofibroblastic tumor arising from soft tissues of extremities harboring a novel CLIP2-ALK fusion.
Ding R; Li X; Zhu XM; Song QX; Fan QH; Zhang ZH; Gong QX
Pathol Int; 2020 Oct; 70(10):798-803. PubMed ID: 32716129
[TBL] [Abstract][Full Text] [Related]
35. A recurrent inflammatory myofibroblastic tumor patient with two novel
Xu X; Li L; Zhang Y; Meng F; Xie H; Duan R
Transl Cancer Res; 2022 Sep; 11(9):3379-3384. PubMed ID: 36237256
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
[TBL] [Abstract][Full Text] [Related]
37. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report.
Zhang P; Wang C; Lv Z; Du M; Xu R
J Cardiothorac Surg; 2023 Nov; 18(1):318. PubMed ID: 37950305
[TBL] [Abstract][Full Text] [Related]
39. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
40. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]